Emergent BioSolutions (STU:ER4) Beta: 1.9744 (As of Jun. 26, 2026)


STU:ER4 Emergent BioSolutions Inc STU:ER4
57 GF Score
Price €6.94
GF Value €4.09
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Emergent BioSolutions Beta?

Emergent BioSolutions STU:ER4 -5.19% 57 Beta is 1.9744 as of Jun. 26, 2026. GuruFocus rates STU:ER4 with a GF Score™ of 57/100 and a GF Value™ of €4.09 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-26), Emergent BioSolutions's Beta is 1.9744.


Emergent BioSolutions  (STU:ER4) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Emergent BioSolutions Beta Related Terms


Emergent BioSolutions Beta Historical Data

* Premium members only.

The historical data trend for Emergent BioSolutions's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emergent BioSolutions Beta Chart

Emergent BioSolutions Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 1.28 0.78 1.47

Emergent BioSolutions Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.30 2.46 2.31 1.47 1.95

STU:ER4 vs AQST, EOLS, ELTP: Beta Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Emergent BioSolutions Beta vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's Beta distribution charts can be found below:

* The bar in red indicates where Emergent BioSolutions's Beta falls into.


STU:ER4
57GF Score
Emergent BioSolutions Inc STU:ER4
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Emergent BioSolutions Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 1.9744 mean?
Emergent BioSolutions (STU:ER4) has a Beta of 1.9744 as of Jun. 26, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Emergent BioSolutions and its competitors.
Is Emergent BioSolutions' Beta too high?
Emergent BioSolutions' current Beta is 1.9744. Overall, Emergent BioSolutions has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Emergent BioSolutions' Beta compare to AQST and EOLS?
Emergent BioSolutions' Beta of 1.9744 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Drug Manufacturers company?
A good Beta depends on the Drug Manufacturers industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Emergent BioSolutions and its competitors. Emergent BioSolutions's current Beta is 1.9744. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emergent BioSolutions stock overvalued right now?
Based on GuruFocus' analysis, Emergent BioSolutions (STU:ER4) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.09, compared to a current price of €6.94 — trading 69.6% above its estimated fair value. The current Beta is 1.9744. Emergent BioSolutions' overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Emergent BioSolutions (STU:ER4), the current Beta is 1.9744 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Emergent BioSolutions (STU:ER4) Overvalued in 2026?

Based on GuruFocus' analysis, Emergent BioSolutions stock appears to be overvalued. The current stock price of €6.94 is trading 69.6% above its estimated GF Value™ of €4.09. GuruFocus considers Emergent BioSolutions to be Significantly Overvalued.

Key valuation signals for STU:ER4:

  • Beta: 1.9744
  • GF Value™: €4.09 vs. price of €6.94 (69.6% above fair value)
  • GF Score™: 57/100 with 5 warning signs

No single metric tells the full story. See the STU:ER4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Emergent BioSolutions Business Description

Other Exchanges EBS:USA0IGA:UK
Address 300 Professional Drive, Gaithersburg, MD, USA, 20879
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
57GF Score

Get the complete analysis for STU:ER4

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.94
Price
€4.09
GF Value